



Theraclion's managers and employees invest in equity capital

Long-term alignment of the interests of company's executives and employees
with those of its shareholders

Malakoff – June 29, 2015 – THERACLION (Alternext, FR0010120402 – ALTHE), a company specialized in leading-edge medical equipment for echotherapy, today announced that management and key employees have directly invested over €300,000 in Theraclion's equity capital by buying existing shares. This represents close to 60,000 shares acquired, accounting for 1.38% of total equity capital.

"I'm proud that so many of our employees have invested in Theraclion's equity. It underlines Theraclion management and employees' confidence in the development of the Echopulse system and their commitment to expanding the client base. It represents the long-term alignment of the interests of the company's executives and employees with those of its shareholders while helping to attract and retain key executives and employees. Lastly, it reflects their commitment to the innovative echotherapy project", commented David Caumartin, CEO of Theraclion.

16 managers and employees (out of 25 total) have invested in the Company's equity capital by purchasing Theraclion shares with their own resources. This will contribute to driving long-term Shareholder Value.

About Theraclion

Theraclion is a French company specializing in high-tech medical equipment using therapeutic ultrasound. Drawing on leading-edge technologies, Theraclion has designed and manufactured an innovative solution for echotherapy, the Echopulse®, allowing non-invasive tumor treatment through ultrasound-guided high-intensity focused ultrasound.

Theraclion is ISO 13485 certified and has received the CE mark for non-invasive ablation of breast fibroadenomas and thyroid nodules. Based in Malakoff, near Paris, France Theraclion has brought together a team of 25 people, 52 percent of whom are dedicated to R&D and clinical trials. For more information, please visit Theraclion's website: www.theraclion.com.

Theraclion is listed on Alternext Paris

PEA-PME Eligible

Mnemonic: ALTHE - ISIN Code: FR0010120402



Contacts:

Theraclion

David Caumartin

CEO

Tel.: +33 (0)1 55 48 90 70

david.caumartin@theraclion.com

NewCap

Financial Communications & Investors relations

Emmanuel Huynh / Valentine Brouhot

Tel.: +33 (0)1 44 71 94 94

theraclion@newcap.fr

Kalima

Press Relations

Estelle Reine-Adélaïde/ Florence Calba

Tel. : + 33 (0)1 44 90 82 54

era@kalima-rp.fr